• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Avascular Necrosis Market Trends

    ID: MRFR/MED/4673-CR
    539 Pages
    Kinjoll Dey
    June 2018

    Avascular Necrosis Market Research Report Information By Type (Trauma Related Avascular Necrosis (AVN) and Non-Trauma Related Avascular Necrosis (AVN)0, By Treatment (Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Cholesterol Lowing Drugs, Osteoporosis Drugs, Blood Thinners, and Others), By Diagnosis (Imaging, Biopsy, CT Scan, PET and X- Ray), By End User (Hospital Pharmacies, Retail Pharmacies...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Avascular Necrosis Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Trends

    Key Emerging Trends in the Avascular Necrosis Market

    People are preferring synthetic bone-grafts over natural ones like allografts and bovine-derived grafts. The issue with natural materials is their varied particle size. Now, the trend is leaning toward synthetic grafts made of ceramics and polymers because they can be precisely manufactured. This shift to synthetic grafts is likely to impact the market's growth positively. Nanomedicine is all about using tiny technology in medicine. Nanotechnology is about controlling really small particles, smaller than 100 nanometers. These particles are stronger and more durable than regular ones and can be made really small. This smaller size means less harm and quicker healing. Using nanotechnology can also help save costs by reducing material volume. However, nanotechnology is new and needs more testing to make sure it's safe and useful. So, researchers are working on making lightweight and compact implants using nanotechnology, which is helping the market grow. There's a growing need to improve synthetic bone grafts. Some synthetic materials don’t have the organic stuff that helps bone grow. To fix this, scientists are using recombinant DNA technology to mix these materials with growth factors. This helps enhance the grafts and stem cell-based autografts. The use of biotechnology is expected to improve synthetic bone grafts’ characteristics like bone growth, and this is expected to boost the market. Titanium-foam implants are being developed for bone grafting. These implants are like natural bone in structure and fit better into the body. They have properties similar to bones and are stronger and more flexible than other synthetic materials. This research on stronger synthetic grafts is expected to have a faster growth rate. 3D bioprinting is a groundbreaking technology allowing custom-made bone graft products. This involves creating these products by layering materials based on a digital 3D model. This technology has been used for creating prosthetics, dental implants, human organs, and tissue. It can also make degradable bone grafts, controlling their strength and materials. This could reduce the need for organ donation and lower the risk of rejection. The development of these 3D printed implants is expected to boost the market by offering personalized bone grafts and minimizing organ donations.

    Market Summary

    The Global Avascular Necrosis Market is projected to grow from 0.56 USD Billion in 2024 to 1.04 USD Billion by 2035.

    Key Market Trends & Highlights

    Avascular Necrosis Key Trends and Highlights

    • The market is expected to witness a compound annual growth rate (CAGR) of 5.73 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 1.04 USD Billion, indicating robust growth potential.
    • in 2024, the market is valued at 0.56 USD Billion, reflecting the current demand for treatment options.
    • Growing adoption of innovative treatment modalities due to increasing prevalence of avascular necrosis is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.56 (USD Billion)
    2035 Market Size 1.04 (USD Billion)
    CAGR (2025-2035) 5.72%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Dr. Reddy’s Laboratories Ltd., Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V, Zimmer Biomet, Merck & Co. Inc, Enzo Biochem Inc, Atnahs, Bone Therapeutics, SAVericel Corporation

    Market Trends

    Growing accidents is driving the market growth

    Market CAGR for avascular necrosis is being driven by the rising fatal accidents. Avascular necrosis is a condition that develops after a fractured hip or dislocation, a hard impact from an automobile accident, or both. As a result of car collisions in traffic accidents, people might suffer serious injuries such as fractured bones and dislocated hips, as well as blood flow difficulties. Traumatic injuries develop when the femoral head's dislocation and fracture cut off the blood supply to the area. 

    Trauma injuries like fractures to the neck of the talus frequently occur as a result of car accidents, falls, sports injuries, natural disasters, and other physical mishaps that occur at home, at work, and while walking down the street. Avascular Necrosis is another condition commonly affecting kids and is brought on by cancer treatment. 

    Avascular Necrosis of the proximal femoral head is known as Legg-Calvé-Perthes disease (LCPD), and it frequently affects kids between the ages of 4 and 10 years old. As a result, the demand for avascular necrosis market is fueled by the rise in traffic accidents, severe injuries, and occurrence in youngsters.

    The bone marrow aspirate and concentration is a novel, practical method that detects hip avascular necrosis in its early stages. The surgeon removes a sample of the dead hipbone while operating on the bone marrow and replaces it with stem cells obtained from the bone marrow. Thus, bone marrow aspirate and concentration surgery are the most common technology for treating avascular Necrosis. Bone cell treatment, which treats avascular Necrosis (AVN) by employing the patient's cells as a therapeutic instrument, is the only long-term cure for the condition. 

    The disease's progression is stopped by bone cell treatment, improving mobility. Another regenerative medicine technique is tissue engineering, which aids in regenerating the necrotic bone tissues and the vasculature in the femoral head, a key contributor to the condition.

    One of the key factors propelling the avascular necrosis market's revenue growth is the rise in avascular necrosis prevalence caused by an increase in unhealthy behaviors like alcohol or cigarette intake or smoking in a growing population.Avascular necrosis risk is increased by several chronic conditions, including diabetes, HIV, or by some unfavorable reactions to cancer therapy and organ transplants, which helps drive the avascular necrosis market's revenue growth. 

    The market for avascular Necrosis is expanding due to the excessive use of steroids in numerous other treatments, which raises the risk of avascular Necrosis. Thus, driving the Avascular Necrosis market revenue.

    The rising prevalence of avascular necrosis, coupled with advancements in diagnostic techniques and treatment options, suggests a growing need for comprehensive management strategies in the healthcare system.

    Centers for Disease Control and Prevention (CDC)

    Avascular Necrosis Market Market Drivers

    Market Growth Projections

    The Global Avascular Necrosis Market Industry is poised for substantial growth, with projections indicating a market value of 0.56 USD Billion in 2024 and an anticipated increase to 1.04 USD Billion by 2035. This growth reflects a compound annual growth rate (CAGR) of 5.73% from 2025 to 2035, driven by factors such as rising incidence rates, advancements in diagnostics, and increased R&D investments. The market's expansion is indicative of the evolving landscape of AVN treatment and the ongoing commitment to improving patient outcomes.

    Rising Geriatric Population

    The global increase in the geriatric population is a significant factor influencing the Global Avascular Necrosis Market Industry. Older adults are more susceptible to conditions that lead to AVN, such as osteoporosis and other degenerative diseases. As the population aged 65 and above continues to grow, the demand for AVN treatments is expected to rise correspondingly. This demographic shift is likely to contribute to the market's expansion, with projections indicating a market value of 1.04 USD Billion by 2035, as healthcare systems adapt to the needs of an aging population.

    Advancements in Diagnostic Techniques

    Technological advancements in diagnostic imaging, such as MRI and CT scans, enhance the detection of avascular necrosis at earlier stages. These innovations facilitate timely intervention, which is crucial for improving patient outcomes. The Global Avascular Necrosis Market Industry benefits from these advancements, as they lead to increased diagnosis rates and subsequent treatment demand. As healthcare providers adopt these advanced techniques, the market is projected to grow, potentially reaching 1.04 USD Billion by 2035, driven by the need for early and accurate diagnosis.

    Increasing Incidence of Avascular Necrosis

    The rising prevalence of avascular necrosis (AVN) globally is a primary driver for the Global Avascular Necrosis Market Industry. Factors such as increased alcohol consumption, steroid use, and certain medical conditions contribute to the growing incidence of AVN. For instance, studies indicate that approximately 10,000 new cases of AVN are diagnosed annually in the United States alone. This trend suggests a potential market value of 0.56 USD Billion in 2024, reflecting the urgent need for effective treatment options and increased awareness surrounding the condition.

    Enhanced Awareness and Education Initiatives

    Increased awareness and education initiatives regarding avascular necrosis are crucial for the Global Avascular Necrosis Market Industry. Healthcare organizations and advocacy groups are actively working to inform both patients and healthcare providers about the condition, its risk factors, and treatment options. This heightened awareness is likely to lead to earlier diagnosis and treatment, ultimately driving market growth. As more individuals become informed about AVN, the demand for effective therapies is expected to rise, contributing to the market's projected growth trajectory.

    Growing Research and Development Investments

    Increased investments in research and development for AVN treatments are propelling the Global Avascular Necrosis Market Industry forward. Pharmaceutical companies and research institutions are focusing on innovative therapies, including regenerative medicine and stem cell treatments. This surge in R&D is expected to yield new treatment options, enhancing patient care. With a projected compound annual growth rate (CAGR) of 5.73% from 2025 to 2035, the market is likely to expand significantly as new therapies emerge, addressing the unmet needs of AVN patients.

    Market Segment Insights

    Avascular Necrosis Type Insights

    Based on type, the  Avascular Necrosis market segmentation includes trauma-related avascular necrosis (AVN) and non-trauma-related avascular necrosis (AVN). The non-trauma-related avascular necrosis (AVN) segment dominated the market, accounting for 66% of market revenue. The causes of these increases are increased alcohol consumption, metabolic bone disorders, and other illnesses. 

    The main disability in young people is non-traumatic avascular necrosis of the femoral head, which has a high medical cost. The prevalence of femoral head necrosis has significantly grown in recent years due to rising testosterone usage and alcohol consumption.

    Avascular Necrosis Treatment Insights

    Based on Treatment, the  Avascular Necrosis market segmentation includes trauma-related nonsteroidal anti-inflammatory drugs (NSAIDs), cholesterol lowing drugs, osteoporosis drugs, blood thinners, and others. The cholesterol lowing drugs segment dominated the market. This increase is related to the possibility that reducing blood fat and cholesterol levels could prevent arterial blockages that cause avascular necrosis.

    Avascular Necrosis Diagnosis Insights

    Based on diagnosis, the  Avascular Necrosis market segmentation includes imaging, biopsy, CT Scan, PET and X-Ray. The CT scan segment dominated the market. The more accurate test for avascular necrosis diagnosis is CT scan, which is substantially more accurate than simple film radiography in detecting AVN. An in-depth view of the bone is provided by the CT scan, which produces 3D images of the bone. Compared to other diagnostic procedures, it provides a more accurate and conclusive diagnosis of a bone problem. The most common and effective procedure is hence MRI and CT scanning.

    Avascular Necrosis End User Insights

    Based on end users, the  Avascular Necrosis market segmentation includes hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment generated the most income (54%). The segment growth is fueled by the rising need for minimally invasive care and reliance on surgery to address osteonecrosis. Additionally, the market is being driven ahead by regional governments' improvements to the healthcare infrastructure and an increase in hospitalization options. 

    Figure 1  Avascular Necrosis Market, by End User, 2023 & 2032 (USD Billion)

    Source Secondary Research, Primary Research, MRFR Database and Analyst Review

    Get more detailed insights about Avascular Necrosis Market Research Report – Forecast to 2032

    Regional Insights

    By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Avascular Necrosis market area will dominate this market because it places a greater emphasis on the relevance of avascular necrosis in persons and accepts cutting-edge therapeutic techniques with greater frequency. The public's focus on avascular necrosis medical conditions and diagnostics in this area and the expanding senior population will likely drive the market's growth.

    Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 2  AVASCULAR NECROSIS MARKET SHARE BY REGION 2023 (USD Billion)AVASCULAR NECROSIS MARKET SHARE BY REGION 2022

    Source Secondary Research, Primary Research, MRFR Database and Analyst Review

    Europe's Avascular Necrosis market accounts for the second-largest market share, the large population's presence, and the rising number of people with Avascular Necrosis. Further, the German Avascular Necrosis market held the largest market share, and the UK Avascular Necrosis market was the fastest-growing market in the European region.

    Between 2023 and 2032, the Asia-Pacific Avascular Necrosis Market is anticipated to see the fastest CAGR growth. Increasing the number of people with avascular necrosis, government initiatives to enhance public awareness, and a rise in demand for the therapy fuel the market's revenue growth. In addition, the Indian Avascular Necrosis market had the quickest growth rate in the Asia-Pacific region, while China's Avascular Necrosis market had the highest market share.

    Key Players and Competitive Insights

    Leading industry companies are making significant R&D investments to diversify their product offerings, which will drive the Avascular Necrosis market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants also engage in several strategic actions to increase their worldwide presence. The Avascular Necrosis industry must provide affordable products to grow and thrive in a more competitive and challenging market environment.

    Local manufacturing to cut operating costs is one of the key business tactics manufacturers use in the  Avascular Necrosis industry to help clients and expand the market sector In recent years, the Avascular Necrosis industry has offered some of the most significant advantages to medicine. Major players in the Avascular Necrosis market, including Dr. Reddy’s Laboratories Ltd., and others, are attempting to increase market demand by investing in research and development operations.

    Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical firm dedicated to offering cost-effective and cutting-edge medications for better lifestyles. Dr. Reddy offers a variety of goods and services, such as APIs, specialized pharmaceutical services, generics, biosimilars, and differentiated formulations, through its three companies, Pharmaceutical Services & Active Ingredients,  Generics, and Proprietary Products. Our primary therapeutic areas of interest are dermatology, cancer, diabetology, gastroenterology, and diabetology. Dr. Reddy has markets all over the world. The principal markets include the United States, India, the CIS nations, and Europe. 

    In August 2021 As permitted by the U.S. Food and Drug Administration (USFDA), Dr. Reddy's Laboratories Ltd. declared the re-launch of OTC (over-the-counter) Naproxen Sodium Pills USP, 220 mg, the store-brand comparable of Aleve®, in the U.S. market.

    Swiss and Americans founded Novartis AG. Novartis was the fourth largest by sales in 2022 and has consistently been rated in the top five ly. The Novartis Group is run by Novartis AG, a publicly traded Swiss holding corporation. Novartis AG directly or indirectly owns all businesses that function as subsidiaries of the Novartis Group ly. Three operating divisions make up Novartis's businesses Sandoz (generics), Innovative Medicines, and Alcon (eyecare).

    In October 2020, Leqvio (inclisiran) has been approved by the European Commission (EC) for treating people with hypercholesterolemia or mixed dyslipidemia, according to a statement from Novartis. This approval is based on the strong ORION clinical development program's findings, which showed that Leqvio reduced low-density lipoprotein cholesterol (LDL-C) in individuals with increased LDL-C by up to 52% while still maximally tolerated by statin therapy. Leqvio is anticipated to support long-term adherence with two doses per year, after an initial dose and one at three months 1-3.

    Key Companies in the Avascular Necrosis Market market include

    Industry Developments

    Future Outlook

    Avascular Necrosis Market Future Outlook

    The Global Avascular Necrosis Market is projected to grow at a 5.72% CAGR from 2025 to 2035, driven by advancements in treatment options, increasing prevalence, and rising awareness.

    New opportunities lie in:

    • Develop innovative drug delivery systems targeting avascular necrosis.
    • Expand telemedicine services for remote patient monitoring and consultations.
    • Invest in regenerative medicine technologies to enhance bone repair and recovery.

    By 2035, the market is expected to demonstrate robust growth, reflecting advancements in treatment and increased patient access.

    Market Segmentation

    Avascular Necrosis Type Outlook

    • Trauma Related Avascular Necrosis (AVN)
    • Non-Trauma Related Avascular Necrosis (AVN)

    Avascular Necrosis End user Outlook

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Avascular Necrosis Regional Outlook

    • US
    • Canada
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East
    • Africa
    • Latin America

    Avascular Necrosis Diagnosis Outlook

    • Imaging
    • Biopsy
    • CT Scan
    • PET
    • X- Ray

    Avascular Necrosis Treatment Outlook

    • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
    • Cholesterol Lowing Drugs
    • Osteoporosis Drugs
    • Blood Thinners
    • Others

    Report Scope

    Avascular Necrosis Report Scope

    Report Attribute/Metric Details
    Market Size 2024 USD 0.564 Billion
    Market Size 2035 1.04 (Value (USD Billion))
    Compound Annual Growth Rate (CAGR) 5.72% (2025 - 2035)
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2018- 2022
    Market Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Type, Treatment End User, and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Novartis AGPfizer Inc.Teva Pharmaceutical Industries Ltd.Mylan N.V.Zimmer Biomet Merck & Co. Inc.Enzo Biochem Inc.Atnahs Bone Therapeutics SAVericel Corporation
    Key Market Opportunities Growing technology
    Key Market Dynamics Increase in fatal accidents
    Market Size 2025 0.60 (Value (USD Billion))

    Market Highlights

    Author

    Kinjoll Dey
    Research Analyst Level I

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    What is the projected growth of the Avascular Necrosis market?

    The Avascular Necrosis market is the expected increase in total market value of 1.04 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

    What is the size of the Avascular Necrosis market?

    Avascular Necrosis market size was valued at approximately 0.56 billion USD in 2024. This figure will reach 1.04 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

    What is the CAGR of the Avascular Necrosis market?

    Avascular Necrosis market is expected to grow at a CAGR of 5.72% between 2025 and 2035.

    How much will the Avascular Necrosis market be worth by 2035?

    Avascular Necrosis market is expected to be worth of 1.04 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

    How will the Avascular Necrosis market perform over the next 10 years?

    Over the next 10 years the Avascular Necrosis market is expected to shift from usd billion 0.56 to 1.04 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

    Which region held the largest market share in the Avascular Necrosis market?

    North America had the largest share in the market

    1. Executive Summary
    2. Market Introduction
      1. Scope Of Study 32
      2. Research Objective 32
      3. List Of Assumptions 32
      4. Market Structure 33
    3. Research Methodology
      1. Research Process 35
      2. Primary Research 36
      3. Secondary Research 37
      4. Market Size Estimation 37
      5. Forecast Model 38
    4. Market Dynamics
      1. Introduction 40
      2. Drivers 41
        1. Increasing Awareness Along With The High Prevalence Of The Avascular Necrosis Disease 41
        2. Rising Preference Of Surgeries To Cure Osteonecrosis 41
        3. Rising Preference Of Bone Grafting Surgical Procedures With The Less Pain Substitute Procedures 41
        4. Consolidation Of Large Healthcare Providers In The U.S. 42
        5. Technological Advancements In The Development Of Surgical Implants 42
      3. Restraints 42
        1. The High Cost Of Surgical Procedures And Related Side Effects 42
        2. Worsening Regulatory Landscape And Growing Cost Of Noncompliance In Developed Countries 43
      4. Opportunities 43
        1. Growing Demand For Non-Invasive Treatments For Faster Recovery 43
      5. Technology Trends & Assessment 44
        1. Acceptance Of Synthetic Bone-Graft Over Natural Ones 44
        2. Nanotechnology 44
        3. Rising Demand For Incorporating Recombinant DNA Technology In Surgical Implants 44
        4. Development Of Titanium-Foam Implant For Bone Grafting 44
        5. Customized Degradable Implants 44
    5. Market Factor Analysis
      1. Porter’s Five Forces Model 46
        1. Bargaining Power Of Suppliers 46
        2. Bargaining Power Of Buyers 47
        3. Threat Of New Entrants 47
        4. Threat Of Substitutes 47
        5. Intensity Of Rivalry 48
      2. Value Chain Analysis 48
        1. Research & Development 48
        2. Manufacturing 49
        3. Distribution 49
        4. Marketing & Sales 49
        5. Post-Sales Monitoring 49
      3. Epidemiology Of Avascular Necrosis 49
    6. Avascular Necrosis Market, By Type
      1. Introduction 54
      2. Non-Trauma Related Avascular Necrosis 55
        1. Age Group 56
        2. Causes 58
      3. Trauma-Related Avascular Necrosis 62
    7. Avascular Necrosis Market, By Site
      1. Introduction 64
      2. Hip Bone 65
      3. Knee 66
      4. Shoulder 67
    8. Avascular Necrosis Market, By Diagnosis
      1. Introduction 69
      2. Imaging 70
        1. X-Ray 72
        2. CT Scan 72
        3. MRI 73
        4. PET 74
      3. Biopsy 74
    9. Avascular Necrosis Market, By Treatment
      1. Introduction 77
      2. Medication 78
        1. Medication By NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) 79
        2. Medication By Bisphosphonates 79
        3. Medication By Blood Thinners 80
      3. Electrical Stimulation 81
      4. Gene Therapy 82
      5. Surgery 82
        1. Core Decompression 83
        2. Osteotomy 84
        3. Bone Graft 85
        4. Arthoplasty 85
    10. Avascular Necrosis Market, By End-User
      1. Introduction 88
      2. Hospitals & Clinics 89
      3. Diagnostic Centers 90
      4. Ambulatory Surgical Centers 91
    11. Global Avascular Necrosis Market, By Region
      1. Introduction 93
      2. Americas 103
    12. Avascular Necrosis Market, By Type
    13. Avascular Necrosis Market, By Site
    14. Avascular Necrosis Market, By Diagnosis
    15. Avascular Necrosis Market, By Treatment
    16. Avascular Necrosis Market, By End-User
      1. North America 112
    17. Avascular Necrosis Market, By Site
    18. Avascular Necrosis Market, By Diagnosis
    19. Avascular Necrosis Market, By Treatment
    20. Avascular Necrosis Market, By End-User
      1. U.S. 123
    21. Avascular Necrosis Market, By Type
    22. Avascular Necrosis Market, By Diagnosis
      1. Canada. 131
    23. Avascular Necrosis Market, By Site
      1. South America 140
      2. Europe 149
        1. Western Europe 160
    24. Avascular Necrosis Market, By End-User
      1. France 179
    25. Avascular Necrosis Market, By Type
    26. Avascular Necrosis Market, By Diagnosis
      1. UK 188
    27. Avascular Necrosis Market, By Type
    28. Avascular Necrosis Market, By Treatment
      1. Italy 197
        1. Spain 206
        2. Eastern Europe 224
    29. Avascular Necrosis Market, By Site
      1. Asia Pacific 232
        1. Japan 243
        2. China 251
        3. India 260
        4. Australia 268
        5. Republic Of Korea 277
        6. Rest Of Asia Pacific 285
    30. Avascular Necrosis Market, By Type
      1. The Middle East & Africa 294
        1. Middle East 303
    31. Competitive Landscape
      1. Introduction 324
      2. Company Market Share Analysis 325
        1. Introduction 325
      3. Key Developments 326
    32. Company Profiles
      1. Sanofi 330
        1. Company Overview 330
        2. Financial Overview 330
        3. Products Offering 331
        4. Key Developments 331
        5. SWOT Analysis 331
        6. Key Strategy 331
      2. Bayer Healthcare AG 332
        1. Company Overview 332
        2. Financial Overview 332
        3. Products Offering 333
        4. Key Developments 333
        5. SWOT Analysis 333
        6. Key Strategy 333
      3. Boehringer Ingelheim GmbH 334
        1. Company Overview 334
        2. Financial Overview 334
        3. Products Offering 335
        4. Key Developments 335
        5. SWOT Analysis 335
        6. Key Strategy 335
      4. Pfizer Inc. 336
        1. Company Overview 336
        2. Financial Overview 336
        3. Products Offering 337
        4. Key Developments 337
        5. SWOT Analysis 337
        6. Key Strategy 337
      5. Merck KGaA 338
        1. Company Overview 338
        2. Financial Overview 338
        3. Products Offering 339
        4. Key Developments 339
        5. SWOT Analysis 339
        6. Key Strategy 339
      6. Stryker Corporation 340
        1. Company Overview 340
        2. Financial Overview 340
        3. Products Offering 341
        4. Key Developments 341
        5. SWOT Analysis 342
        6. Key Strategy 342
      7. Medtronic PLC 343
        1. Company Overview 343
        2. Financial Overview 343
        3. Products Offering 344
        4. Key Developments 344
        5. SWOT Analysis 344
        6. Key Strategy 344
      8. Aurobindo Pharma 345
        1. Company Overview 345
        2. Financial Overview 345
        3. Products Offering 346
        4. Key Developments 346
        5. SWOT Analysis 347
        6. Key Strategy 347
      9. Integra LifeSciences Corporation 348
        1. Company Overview 348
        2. Financial Overview 348
        3. Products Offering 349
        4. Key Developments 349
        5. SWOT Analysis 349
        6. Key Strategy 349
      10. Zimmer Biomet Holdings 350
        1. Company Overview 350
        2. Financial Overview 350
        3. Products Offering 351
        4. Key Developments 351
        5. SWOT Analysis 352
        6. Key Strategy 352
      11. Wright Medical Group N.V. 353
        1. Company Overview 353
        2. Financial Overview 353
        3. Products Offering 354
        4. Key Developments 354
        5. SWOT Analysis 355
        6. Key Strategy 355
      12. Grifols SA 356
        1. Company Overview 356
        2. Financial Overview 356
        3. Products Offering 357
        4. Key Developments 357
        5. SWOT Analysis 357
        6. Key Strategy 357
      13. Smith & Nephew 358
        1. Company Overview 358
        2. Financial Overview 358
        3. Products Offering 359
        4. Key Developments 359
        5. SWOT Analysis 360
        6. Key Strategy 360
      14. Ethicon Inc. 361
        1. Company Overview 361
        2. Financial Overview 361
        3. Products Offering 362
        4. Key Developments 362
        5. SWOT Analysis 363
        6. Key Strategy 363
    33. Conclusion
      1. Key Findings 365
        1. CEO’s Viewpoint 365
        2. Unmet Needs 365
        3. Key Companies To Watch 365
        4. Prediction 365
    34. Appendix
      1. Discussion Blue Print 367
    35. List of Tables and Figures
      1. 16 List Of Tables
      2. TABLE 1 MARKET SYNOPSIS 30
      3. TABLE 2 LIST OF ASSUMPTIONS 32
      4. TABLE 3 NORTH AMERICA PROCEDURE NUMBERS, 2020–2016 (UNITS) 50
      5. TABLE 4 NORTH AMERICA PROCEDURE NUMBERS, 2027–2027 (UNITS) 50
      6. TABLE 5 SOUTH AMERICA PROCEDURE NUMBERS, 2020–2016 (UNITS) 50
      7. TABLE 6 SOUTH AMERICA PROCEDURE NUMBERS, 2027–2027 (UNITS) 50
      8. TABLE 7 EUROPE PROCEDURE NUMBERS, 2020–2016 (UNITS) 51
      9. TABLE 8 EUROPE PROCEDURE NUMBERS, 2027–2027 (UNITS) 51
      10. TABLE 9 ASIA PACIFIC PROCEDURE NUMBERS, 2020–2016 (UNITS) 51
      11. TABLE 10 ASIA PACIFIC PROCEDURE NUMBERS, 2027–2027 (UNITS) 51
      12. TABLE 11 MIDDLE EAST PROCEDURE NUMBERS, 2020–2016 (UNITS) 52
      13. TABLE 12 MIDDLE EAST PROCEDURE NUMBERS, 2027–2027 (UNITS) 52
      14. TABLE 13 AFRICA PROCEDURE NUMBERS, 2020–2016 (UNITS) 52
      15. TABLE 14 AFRICA PROCEDURE NUMBERS, 2027–2027 (UNITS) 52
      16. TABLE 15 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 54
      17. TABLE 16 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 54
      18. TABLE 17 GLOBAL AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 55
      19. TABLE 18 GLOBAL AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 56
      20. TABLE 19 GLOBAL AVASCULAR NECROSIS MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 56
      21. TABLE 20 GLOBAL AVASCULAR NECROSIS MARKET, BY AGE GROUP,2020–2027 (USD MILLION) 56
      22. TABLE 21 GLOBAL AVASCULAR NECROSIS MARKET FOR THIRD DECADE, BY REGION 2020–2027 (USD MILLION) 57
      23. TABLE 22 GLOBAL AVASCULAR NECROSIS MARKET FOR THIRD DECADE, BY REGION, 2020–2027 (USD MILLION) 57
      24. TABLE 23 GLOBAL AVASCULAR NECROSIS MARKET FOR FIFTH DECADE, BY REGION, 2020–2027 (USD MILLION) 57
      25. TABLE 24 GLOBAL AVASCULAR NECROSIS MARKET FOR FIFTH DECADE, BY REGION, 2020–2027 (USD MILLION) 58
      26. TABLE 25 GLOBAL AVASCULAR NECROSIS MARKET, BY CAUSES, 2020–2027 (USD MILLION) 58
      27. TABLE 26 GLOBAL AVASCULAR NECROSIS MARKET, BY CAUSES, 2020–2027 (USD MILLION) 59
      28. TABLE 27 GLOBAL AVASCULAR NECROSIS MARKET FOR CAISSON DISEASE, BY REGION, 2020–2027 (USD MILLION) 59
      29. TABLE 28 GLOBAL AVASCULAR NECROSIS MARKET FOR CAISSON DISEASE, BY REGION, 2020–2027 (USD MILLION) 59
      30. TABLE 29 GLOBAL AVASCULAR NECROSIS MARKET FOR SICKLE CELL ANAEMIA, BY REGION, 2020–2027 (USD MILLION) 60
      31. TABLE 30 GLOBAL AVASCULAR NECROSIS MARKET FOR SICKLE CELL ANEMIA, BY REGION, 2020–2027 (USD MILLION) 60
      32. TABLE 31 GLOBAL AVASCULAR NECROSIS MARKET FOR STEROID ABUSE, BY REGION, 2020–2027 (USD MILLION) 60
      33. TABLE 32 GLOBAL AVASCULAR NECROSIS MARKET FOR STEROID ABUSE, BY REGION, 2020–2027 (USD MILLION) 61
      34. TABLE 33 GLOBAL AVASCULAR NECROSIS MARKET FOR ALCOHOL ABUSE, BY REGION, 2020–2027 (USD MILLION) 61
      35. TABLE 34 GLOBAL AVASCULAR NECROSIS MARKET FOR ALCOHOL ABUSE, BY REGION, 2020–2027 (USD MILLION) 61
      36. TABLE 35 GLOBAL AVASCULAR NECROSIS MARKET FOR TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 62
      37. TABLE 36 GLOBAL AVASCULAR NECROSIS MARKET FOR TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 62
      38. TABLE 37 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2020–2027 (USD MILLION) 64
      39. TABLE 38 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2020–2027 (USD MILLION) 65
      40. TABLE 39 GLOBAL AVASCULAR NECROSIS MARKET FOR HIP BONE, BY REGION, 2020–2027 (USD MILLION) 65
      41. TABLE 40 GLOBAL AVASCULAR NECROSIS MARKET, FOR HIP BONE, BY REGION, 2020–2027 (USD MILLION) 66
      42. TABLE 41 GLOBAL AVASCULAR NECROSIS MARKET FOR KNEE, BY REGION, 2020–2027 (USD MILLION) 66
      43. TABLE 42 GLOBAL AVASCULAR NECROSIS MARKET FOR KNEE, BY REGION, 2020–2027 (USD MILLION) 66
      44. TABLE 43 GLOBAL AVASCULAR NECROSIS MARKET FOR SHOULDER, BY REGION, 2020–2027 (USD MILLION) 67
      45. TABLE 44 GLOBAL AVASCULAR NECROSIS MARKET FOR SHOULDER, BY REGION, 2020–2027 (USD MILLION) 67
      46. TABLE 45 GLOBAL AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020–2027 (USD MILLION) 69
      47. TABLE 46 GLOBAL AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020–2027 (USD MILLION) 69
      48. TABLE 47 GLOBAL AVASCULAR NECROSIS MARKET FOR IMAGING, BY REGION, 2020–2027 (USD MILLION) 70
      49. TABLE 48 GLOBAL AVASCULAR NECROSIS MARKET FOR IMAGING, BY REGION, 2020–2027 (USD MILLION) 71
      50. TABLE 49 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020–2027 (USD MILLION) 71
      51. TABLE 50 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020–2027 (USD MILLION) 71
      52. TABLE 51 GLOBAL AVASCULAR NECROSIS MARKET FOR X-RAY, BY REGION, 2020–2027 (USD MILLION) 72
      53. TABLE 52 GLOBAL AVASCULAR NECROSIS MARKET FOR X-RAY , BY REGION, 2020–2027 (USD MILLION) 72
      54. TABLE 53 GLOBAL AVASCULAR NECROSIS MARKET FOR CT SCAN, BY REGION, 2020–2027 (USD MILLION) 72
      55. TABLE 54 GLOBAL AVASCULAR NECROSIS MARKET FOR CT SCAN, BY REGION, 2020–2027 (USD MILLION) 73
      56. TABLE 55 GLOBAL AVASCULAR NECROSIS MARKET FOR MRI, BY REGION, 2020–2027 (USD MILLION) 73
      57. TABLE 56 GLOBAL AVASCULAR NECROSIS MARKET FOR MRI, BY REGION, 2020–2027 (USD MILLION) 73
      58. TABLE 57 GLOBAL AVASCULAR NECROSIS MARKET FOR PET, BY REGION, 2020–2027 (USD MILLION) 74
      59. TABLE 58 GLOBAL AVASCULAR NECROSIS MARKET FOR PET, BY REGION, 2020–2027 (USD MILLION) 74
      60. TABLE 59 GLOBAL AVASCULAR NECROSIS MARKET FOR BIOPSY, BY REGION, 2020–2027 (USD MILLION) 75
      61. TABLE 60 GLOBAL AVASCULAR NECROSIS MARKET FOR BIOPSY, BY REGION, 2020–2027 (USD MILLION) 75
      62. TABLE 61 GLOBAL AVASCULAR NECROSIS MARKET BY TREATMENT, 2020–2027 (USD MILLION) 77
      63. TABLE 62 GLOBAL AVASCULAR NECROSIS MARKET BY TREATMENT, 2020–2027 (USD MILLION) 78
      64. TABLE 63 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, BY REGION, 2020–2027 (USD MILLION) 78
      65. TABLE 64 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, BY REGION, 2020–2027 (USD MILLION) 78
      66. TABLE 65 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020–2027 (USD MILLION) 79
      67. TABLE 66 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020–2027 (USD MILLION) 79
      68. TABLE 67 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020–2027 (USD MILLION) 80
      69. TABLE 68 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020–2027 (USD MILLION) 80
      70. TABLE 69 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020–2027 (USD MILLION) 80
      71. TABLE 70 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020–2027 (USD MILLION) 81
      72. TABLE 71 GLOBAL AVASCULAR NECROSIS MARKET FOR ELECTRICAL STIMULATION, BY REGION, 2020–2027 (USD MILLION) 81
      73. TABLE 72 GLOBAL AVASCULAR NECROSIS MARKET FOR ELECTRICAL STIMULATION, BY REGION, 2020–2027 (USD MILLION) 81
      74. TABLE 73 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 82
      75. TABLE 74 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 82
      76. TABLE 75 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 83
      77. TABLE 76 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 83
      78. TABLE 77 GLOBAL AVASCULAR NECROSIS MARKET FOR CORE DECOMPRESSION, BY REGION, 2020–2027 (USD MILLION) 83
      79. TABLE 78 GLOBAL AVASCULAR NECROSIS MARKET FOR CORE DECOMPRESSION , BY REGION, 2020–2027 (USD MILLION) 84
      80. TABLE 79 GLOBAL AVASCULAR NECROSIS MARKET FOR OSTEOTOMY , BY REGION, 2020–2027 (USD MILLION) 84
      81. TABLE 80 GLOBAL AVASCULAR NECROSIS MARKET FOR OSTEOTOMY, BY REGION, 2020–2027 (USD MILLION) 84
      82. TABLE 81 GLOBAL AVASCULAR NECROSIS MARKET FOR BONE GRAFT, BY REGION, 2020–2027 (USD MILLION) 85
      83. TABLE 82 GLOBAL AVASCULAR NECROSIS MARKET FOR BONE GRAFT, BY REGION, 2020–2027 (USD MILLION) 85
      84. TABLE 83 GLOBAL AVASCULAR NECROSIS MARKET FOR ARTHOPLASTY, BY REGION, 2020–2027 (USD MILLION) 85
      85. TABLE 84 GLOBAL AVASCULAR NECROSIS MARKET FOR ARTHOPLASTY, BY REGION, 2020–2027 (USD MILLION) 86
      86. TABLE 85 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, BY REGION, 2020–2027 (USD MILLION) 88
      87. TABLE 86 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, BY REGION, 2020–2027 (USD MILLION) 88
      88. TABLE 87 GLOBAL AVASCULAR NECROSIS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 89
      89. TABLE 88 GLOBAL AVASCULAR NECROSIS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 89
      90. TABLE 89 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 90
      91. TABLE 90 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSTIC CENTERS , BY REGION, 2020–2027 (USD MILLION) 90
      92. TABLE 91 GLOBAL AVASCULAR NECROSIS MARKET FOR AMBULATORY SURGICAL CENTERS , BY REGION, 2020 2027 (USD MILLION) 91
      93. TABLE 92 GLOBAL AVASCULAR NECROSIS MARKET FOR AMBULATORY SURGICAL CENTERS , BY REGION, 2020–2027 (USD MILLION) 91
      94. TABLE 93 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 93
      95. TABLE 94 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 93
      96. TABLE 95 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 94
      97. TABLE 96 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 94
      98. TABLE 97 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 95
      99. TABLE 98 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 95
      100. TABLE 99 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 95
      101. TABLE 100 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 96
      102. TABLE 101 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 96
      103. TABLE 102 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 96
      104. TABLE 103 GLOBAL AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 97
      105. TABLE 104 GLOBAL AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 97
      106. TABLE 105 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 97
      107. TABLE 106 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 98
      108. TABLE 107 GLOBAL AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 98
      109. TABLE 108 GLOBAL AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 98
      110. TABLE 109 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 99
      111. TABLE 110 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 99
      112. TABLE 111 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 99
      113. TABLE 112 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 100
      114. TABLE 113 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 100
      115. TABLE 114 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 100
      116. TABLE 115 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 101
      117. TABLE 116 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 101
      118. TABLE 117 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 101
      119. TABLE 118 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 102
      120. TABLE 119 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 102
      121. TABLE 120 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 102
      122. TABLE 121 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 103
      123. TABLE 122 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 103
      124. TABLE 123 AMERICAS AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 104
      125. TABLE 124 AMERICAS AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 104
      126. TABLE 125 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 104
      127. TABLE 126 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 105
      128. TABLE 127 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 105
      129. TABLE 128 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 105
      130. TABLE 129 AMERICAS AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 106
      131. TABLE 130 AMERICAS AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 106
      132. TABLE 131 AMERICAS AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 106
      133. TABLE 132 AMERICAS AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 106
      134. TABLE 133 AMERICAS AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 107
      135. TABLE 134 AMERICAS AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 107
      136. TABLE 135 AMERICAS AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 107
      137. TABLE 136 AMERICAS AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 108
      138. TABLE 137 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 108
      139. TABLE 138 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 108
      140. TABLE 139 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 109
      141. TABLE 140 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2023-2032 (USD MILLION) 109
      142. TABLE 141 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 109
      143. TABLE 142 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2023-2032 (USD MILLION) 110
      144. TABLE 143 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 110
      145. TABLE 144 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2023-2032 (USD MILLION) 110
      146. TABLE 145 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 111
      147. TABLE 146 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2023-2032 (USD MILLION) 111
      148. TABLE 147 AMERICAS AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 111
      149. TABLE 148 AMERICAS AVASCULAR NECROSIS MARKET FOR END USER, 2023-2032 (USD MILLION) 112
      150. TABLE 149 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 112
      151. TABLE 150 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2023-2032 (USD MILLION) 112
      152. TABLE 151 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 113
      153. TABLE 152 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2023-2032 114
      154. TABLE 153 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 114
      155. TABLE 154 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2023-2032 (USD MILLION) 114
      156. TABLE 155 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 115
      157. TABLE 156 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2023-2032 (USD MILLION) 115
      158. TABLE 157 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 115
      159. TABLE 158 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2023-2032 (USD MILLION) 116
      160. TABLE 159 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 116
      161. TABLE 160 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2023-2032 (USD MILLION) 116
      162. TABLE 161 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 117
      163. TABLE 162 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2023-2032 (USD MILLION) 117
      164. TABLE 163 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 117
      165. TABLE 164 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2023-2032 (USD MILLION) 118
      166. TABLE 165 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 118
      167. TABLE 166 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2023-2032 (USD MILLION) 118
      168. TABLE 167 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-2032 (USD MILLION) 119
      169. TABLE 168 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2023-20

    Avascular Necrosis Market Segmentation

    Avascular Necrosis Products Type Outlook (USD Billion, 2018-2032)

    • Trauma Related Avascular Necrosis (AVN)
    • Non-Trauma Related Avascular Necrosis (AVN)

    Avascular Necrosis Treatment Outlook (USD Billion, 2018-2032)

    • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
    • Cholesterol Lowing Drugs
    • Osteoporosis Drugs
    • Blood Thinners
    • Others

    Avascular Necrosis Diagnosis Outlook (USD Billion, 2018-2032)

    • Imaging
    • Biopsy
    • CT Scan
    • PET
    • X- Ray

    Avascular Necrosis End user Outlook (USD Billion, 2018-2032)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Avascular Necrosis Products Regional Outlook (USD Billion, 2018-2032)

    • North America Outlook (USD Billion, 2018-2032)

      • North America Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • North America Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • North America Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • North America Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • US Outlook (USD Billion, 2018-2032)

      • US Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • US Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • US Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • US Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • CANADA Outlook (USD Billion, 2018-2032)

      • CANADA Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • CANADA Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • CANADA Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • CANADA Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

    • Europe Outlook (USD Billion, 2018-2032)

      • Europe Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • Europe Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • Europe Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • Europe Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • Germany Outlook (USD Billion, 2018-2032)

      • Germany Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • Germany Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • Germany Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • Germany Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • France Outlook (USD Billion, 2018-2032)

      • France Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • France Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • France Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • France Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • UK Outlook (USD Billion, 2018-2032)

      • UK Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • UK Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • UK Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • UK Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • ITALY Outlook (USD Billion, 2018-2032)

      • ITALY Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • ITALY Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • ITALY Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • ITALY Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • SPAIN Outlook (USD Billion, 2018-2032)

      • Spain Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • Spain Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • Spain Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • Spain Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • Rest Of Europe Outlook (USD Billion, 2018-2032)

      • Rest Of Europe Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • Rest Of Europe Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • Rest Of Europe Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • Rest Of Europe Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

    • Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Asia-Pacific Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • Asia-Pacific Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • Asia-Pacific Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • Asia-Pacific Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • China Outlook (USD Billion, 2018-2032)

      • China Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • China Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • China Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • China Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • Japan Outlook (USD Billion, 2018-2032)

      • Japan Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • Japan Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • Japan Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • Japan Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • India Outlook (USD Billion, 2018-2032)

      • India Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • India Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • India Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • India Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • Australia Outlook (USD Billion, 2018-2032)

      • Australia Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)

      • Australia Avascular Necrosis by Treatment

        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others

      • Australia Avascular Necrosis by Diagnosis

        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray

      • Australia Avascular Necrosis by End user

        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Rest of Asia-Pacific Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • Rest of Asia-Pacific Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • Rest of Asia-Pacific Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • Rest of Asia-Pacific Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

    • Rest of the World Outlook (USD Billion, 2018-2032)

      • Rest of the World Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • Rest of the World Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • Rest of the World Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • Rest of the World Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • Middle East Outlook (USD Billion, 2018-2032)

      • Middle East Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • Middle East Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • Middle East Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • Middle East Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • Africa Outlook (USD Billion, 2018-2032)

      • Africa Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • Africa Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • Africa Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • Africa Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies

      • Latin America Outlook (USD Billion, 2018-2032)

      • Latin America Avascular Necrosis Products by Type
        • Trauma Related Avascular Necrosis (AVN)
        • Non-Trauma Related Avascular Necrosis (AVN)
      • Latin America Avascular Necrosis by Treatment
        • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cholesterol Lowing Drugs
        • Osteoporosis Drugs
        • Blood Thinners
        • Others
      • Latin America Avascular Necrosis by Diagnosis
        • Imaging
        • Biopsy
        • CT Scan
        • PET
        • X- Ray
      • Latin America Avascular Necrosis by End user
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027